GenrAb uses the power of adaptive human immunity to develop neuroprotective and neurotherapeutic human antibodies.
GenrAb has raised $5.6M in total funding. The most recent round was Seed. The last funding was announced in April 2025.
GenrAb's investors include Actium Group.
GenrAb is headquartered in Dallas, United States.
GenrAb uses the power of adaptive human immunity to develop neuroprotective and neurotherapeutic human antibodies.
GenrAb is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"GenrAb — Funding & Investors." VCBacked, April 22, 2025, https://www.vcbacked.co/company/genrab. Accessed August 1, 2026.
VCBacked. (2025). GenrAb — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/genrab
{{cite web |title=GenrAb — Funding & Investors |url=https://www.vcbacked.co/company/genrab |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated